Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

It was Round 2 of raids against vape shops in Westmoreland ... The effort came on the heels of Thursday’s raids by authorities at Vape and Smoke City in Hempfield, EZ Tobacco and Vape in Delmont ...

“EZ Tobacco and Vape” in Delmont, “Vape and Smoke” in Hempfield Township and “The Vape Escape” in Latrobe are all accused of selling illegal products or legal products to underage buyers.

The raids took place at EZ Tobacco & Vape in Delmont, Vape & Smoke City in Hempfield and The Vape EXcape in Latrobe. It was a joint effort by local and state police, as well as Westmoreland County ...

A disposable vape sells for £3-£10 depending on the brand, with the total e-cigarette industry worth an estimated £2.8billion in Britain. There has been a 50 per cent rise in the last year in ...

Patients taking Novo Nordisk A/S’s Ozempic were at significantly ... surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity. The study looked at semaglutide, the main ...

Defra pointed out that vape usage in England grew by more than 400% between 2012 and 2023. Some 9.3% of the British public now buy and use the products. Due to the huge increase and the single-use ...

It is also aimed at reducing problems caused by the disposal of lithium ... laws in place which make it a legal requirement for vape traders not to sell to children under the age of 18 and to ...

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes ...

Denmark unveiled an Nvidia-powered supercomputer that will be used by researchers from Novo Nordisk A/S and other Danish pharmaceutical companies as they seek novel drugs and smarter trial designs.

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...